• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

诱导化疗联合放化疗与单纯放化疗治疗食管鳞癌的疗效比较 诱导化疗治疗食管鳞癌。

Outcomes of Induction Chemotherapy Followed by Chemoradiotherapy Versus Chemoradiotherapy Alone in Esophageal Squamous Cell Carcinoma Induction chemotherapy in Esophageal Squamous Cell Carcinoma.

机构信息

School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Department of Radiation Oncology, Iran University of Medical Sciences, Tehran, Iran.

出版信息

Asian Pac J Cancer Prev. 2024 Apr 1;25(4):1183-1188. doi: 10.31557/APJCP.2024.25.4.1183.

DOI:10.31557/APJCP.2024.25.4.1183
PMID:38679976
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11162715/
Abstract

BACKGROUND

There is still no definite conclusion regarding the effect of Induction Chemotherapy (IC) combined with concurrent Chemoradiotherapy (CRT). Thus this study was aimed to assess outcomes of IC followed By CRT versus CRT alone in Esophageal Squamous Cell Carcinoma (ESCC).

METHODS

This multicenter retrospective study performed on 105 patients who underwent CRT and 73 patients who underwent IC+CRT, between January 2016 and December 2018. The primary endpoints were OS (from the date of treatment to the date of death or 3- years follow-Up). The toxicities of CRT were graded according to the National Cancer Institute Common Toxicity Criteria (version 3.0).

RESULTS

one-year (73.8% vs. 53.2%) and 2-year (53.4% vs. 38.5%) OS rate of the IC+CRT group was significantly higher than that of the CRT group (p < 0.05). No statistically significant differences were observed between the IC+CRT group and the CRT group (31.5% vs. 27.4%) in terms of the 3-year OS rate (p > 0.05). In multivariate logistic regression, age<60 (OR: 1.48; CI 95% 1.02-1.97), clinical staging II (OR: 1.36; CI 95% 1.11-1.88), and the addition of IC (OR: 1.66; CI 95% 1.07-2.19) were independent prognostic factors that affected survival positively.

CONCLUSION

Our data demonstrated that a combination of IC and CRT might be a promising treatment strategy to further improve OS in ESCC patients.

摘要

背景

诱导化疗(IC)联合同期放化疗(CRT)的效果仍无明确结论。因此,本研究旨在评估 IC 后 CRT 与单纯 CRT 治疗食管鳞癌(ESCC)的结果。

方法

本多中心回顾性研究纳入 2016 年 1 月至 2018 年 12 月期间接受 CRT 治疗的 105 例患者和接受 IC+CRT 治疗的 73 例患者。主要终点是总生存期(从治疗开始到死亡或 3 年随访)。CRT 的毒性根据国家癌症研究所通用毒性标准(第 3.0 版)进行分级。

结果

IC+CRT 组的 1 年(73.8%比 53.2%)和 2 年(53.4%比 38.5%)总生存率显著高于 CRT 组(p<0.05)。在 3 年总生存率方面,IC+CRT 组与 CRT 组(31.5%比 27.4%)无统计学差异(p>0.05)。多因素逻辑回归分析显示,年龄<60 岁(OR:1.48;95%CI 1.02-1.97)、临床分期 II 期(OR:1.36;95%CI 1.11-1.88)和 IC 加用(OR:1.66;95%CI 1.07-2.19)是影响生存的独立预后因素。

结论

我们的数据表明,IC 联合 CRT 可能是一种有前途的治疗策略,可以进一步提高 ESCC 患者的总生存率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5b/11162715/f814e80f4475/APJCP-25-1183-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5b/11162715/f814e80f4475/APJCP-25-1183-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a5b/11162715/f814e80f4475/APJCP-25-1183-g001.jpg

相似文献

1
Outcomes of Induction Chemotherapy Followed by Chemoradiotherapy Versus Chemoradiotherapy Alone in Esophageal Squamous Cell Carcinoma Induction chemotherapy in Esophageal Squamous Cell Carcinoma.诱导化疗联合放化疗与单纯放化疗治疗食管鳞癌的疗效比较 诱导化疗治疗食管鳞癌。
Asian Pac J Cancer Prev. 2024 Apr 1;25(4):1183-1188. doi: 10.31557/APJCP.2024.25.4.1183.
2
Long-term results of induction chemotherapy for non-operable esophageal squamous cell carcinoma followed by concurrent chemoradiotherapy: a single-centre experience.不能手术的食管鳞癌诱导化疗后同期放化疗的长期结果:单中心经验。
Radiol Oncol. 2024 Sep 15;58(3):444-457. doi: 10.2478/raon-2024-0038. eCollection 2024 Sep 1.
3
Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma.含铂化疗联合根治性放疗治疗局部晚期食管鳞癌老年患者的获益。
Radiat Oncol. 2021 Oct 30;16(1):207. doi: 10.1186/s13014-021-01931-1.
4
Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy.食管癌患者对放化疗的临床反应与生存和巩固化疗的获益有关。
Cancer Med. 2020 Aug;9(16):5881-5888. doi: 10.1002/cam4.3273. Epub 2020 Jul 6.
5
TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.TENERGY:特瑞普利单抗单药治疗联合 5-FU 顺铂放化疗用于不可切除局部晚期食管鳞癌的多中心 II 期研究。
BMC Cancer. 2020 Apr 20;20(1):336. doi: 10.1186/s12885-020-06716-5.
6
Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial.诱导化疗联合根治性放化疗对比单纯放化疗治疗食管鳞癌的随机 II 期临床研究
Nat Commun. 2021 Jun 29;12(1):4014. doi: 10.1038/s41467-021-24288-1.
7
Clinical outcomes and toxicities of locally advanced esophageal squamous cell carcinoma patients treated with early thoracic radiation therapy after induction chemotherapy.诱导化疗后接受早期胸部放疗的局部晚期食管鳞状细胞癌患者的临床结局和毒性反应
Int J Clin Oncol. 2023 Apr;28(4):550-564. doi: 10.1007/s10147-023-02299-w. Epub 2023 Feb 3.
8
Adjuvant chemotherapy does not benefit patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.辅助化疗对接受根治性放化疗的食管鳞癌患者无益。
Radiat Oncol. 2018 Aug 15;13(1):150. doi: 10.1186/s13014-018-1086-y.
9
Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study.诱导免疫治疗联合化疗后行根治性放化疗治疗局部晚期食管鳞癌:一项倾向评分匹配研究。
Cancer Immunol Immunother. 2024 Feb 16;73(3):55. doi: 10.1007/s00262-024-03649-x.
10
A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.一项关于多西他赛、顺铂和氟尿嘧啶(DCF)诱导化疗后进行放化疗的前瞻性、多中心I/II期研究,该研究针对不可切除的局部晚期食管癌患者。
Cancer Chemother Pharmacol. 2016 Jul;78(1):91-9. doi: 10.1007/s00280-016-3062-2. Epub 2016 May 18.

本文引用的文献

1
Addition of Induction or Consolidation Chemotherapy in Definitive Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone for Patients With Unresectable Esophageal Cancer: A Systematic Review and Meta-Analysis.不可切除食管癌患者在根治性同步放化疗中加用诱导或巩固化疗与单纯同步放化疗的疗效比较:一项系统评价和Meta分析
Front Oncol. 2021 Sep 13;11:665231. doi: 10.3389/fonc.2021.665231. eCollection 2021.
2
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial.新辅助放化疗联合手术治疗食管癌的 10 年结果:随机对照 CROSS 试验。
J Clin Oncol. 2021 Jun 20;39(18):1995-2004. doi: 10.1200/JCO.20.03614. Epub 2021 Apr 23.
3
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
4
LncRNA FAM83A-AS1 aggravates the malignant development of esophageal cancer by binding to miR-495-3p.长链非编码 RNA FAM83A-AS1 通过与 miR-495-3p 结合促进食管癌的恶性发展。
Eur Rev Med Pharmacol Sci. 2020 Sep;24(18):9408-9415. doi: 10.26355/eurrev_202009_23024.
5
Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.2018 年宫颈癌发病率和死亡率的估计:全球分析。
Lancet Glob Health. 2020 Feb;8(2):e191-e203. doi: 10.1016/S2214-109X(19)30482-6. Epub 2019 Dec 4.
6
Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE).三模式联合治疗诱导多西紫杉醇加顺铂和氟尿嘧啶与局部晚期不可切除的胸段食管鳞状细胞癌的标准放化疗的 III 期研究(JCOG1510:TRIANgLE)
Jpn J Clin Oncol. 2019 Dec 18;49(11):1055-1060. doi: 10.1093/jjco/hyz112.
7
Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment.新辅助化疗在三模态治疗后病理完全缓解的食管鳞癌患者中改善预后:辅助治疗的假设产生。
Eur J Surg Oncol. 2019 Aug;45(8):1498-1504. doi: 10.1016/j.ejso.2019.03.020. Epub 2019 Mar 19.
8
Concurrent Selective Lymph Node Radiotherapy and S-1 Plus Cisplatin for Esophageal Squamous Cell Carcinoma: A Phase II Study.同期选择性淋巴结放疗联合 S-1 顺铂治疗食管鳞癌:一项 II 期研究。
Ann Surg Oncol. 2019 Jun;26(6):1886-1892. doi: 10.1245/s10434-019-07264-4. Epub 2019 Feb 25.
9
Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial.新辅助放化疗联合手术对比单纯手术治疗局部进展期食管鳞癌(NEOCRTEC5010):一项 III 期、多中心、随机、开放标签临床试验。
J Clin Oncol. 2018 Sep 20;36(27):2796-2803. doi: 10.1200/JCO.2018.79.1483. Epub 2018 Aug 8.
10
Comparative Outcomes of Induction Chemotherapy Followed By Definitive Chemoradiotherapy versus Chemoradiotherapy Alone In Esophageal Squamous Cell Carcinoma.食管鳞状细胞癌中诱导化疗后行根治性放化疗与单纯放化疗的比较结果
J Cancer. 2017 Sep 20;8(17):3441-3447. doi: 10.7150/jca.21131. eCollection 2017.